WO2026109026 - PCSK9 AND LP(A) DUAL-TARGET COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/109026
Publication Date
28.05.2026
International Application No.
PCT/CN2025/137086
International Filing Date
24.11.2025
Title **
[English]
PCSK9 AND LP(A) DUAL-TARGET COMPOUND AND USE THEREOF
[French]
COMPOSÉ À DOUBLE CIBLE PCSK9 ET LP(A) ET SON UTILISATION
[Chinese]
PCSK9和Lp(a)双靶化合物与应用
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
LAI, Yingjie
LI, Zhongle
QI, Yinliang
QING, Zhineng
WU, Kang
LI, Hongchao
LIU, Wenjuan
Priority Data
202411697753.2
25.11.2024
CN
202411801080.0
06.12.2024
CN
202510220255.7
26.02.2025
CN
202510482858.4
17.04.2025
CN
202511685302.1
17.11.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1841 | |
| EPO | Filing, Examination, Granting | 11786 | |
| Japan | Filing, Examination, Granting | 2018 | |
| South Korea | Filing, Examination, Granting | 1918 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,303
Contact Us
Abstract[English]
The present invention relates to the field of chemical drug technology, and in particular, to a PCSK9 and Lp(a) dual-target compound, an isomer thereof, or a racemate thereof, or a pharmaceutically acceptable salt thereof, a method for preparing same, and use thereof. Also disclosed are a method for using same as a PCSK9 and Lp(a) inhibitor, and a method for treating multiple specific diseases or conditions using same. Formula I[French]
La présente invention relève du domaine de la technologie des médicaments chimiques, et concerne en particulier un composé à double cible PCSK9 et Lp(a), un isomère de celui-ci, ou un racémate de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, un procédé de préparation correspondant et une utilisation associée. L'invention concerne également un procédé d'utilisation de celui-ci en tant qu'inhibiteur de PCSK9 et Lp(a), et une méthode de traitement de multiples maladies ou états spécifiques l'utilisant. Formule I[Chinese]
本发明属于化学药物技术领域，涉及PCSK9和Lp(a)双靶化合物，或其异构体、或其消旋体、或其可药用的盐，及其制备方法与应用。作为一种PCSK9和Lp(a)抑制剂，以及使用其治疗多种特定疾病或病状的方法。式I